Categories
Lung Cancer

Biomarker Discovery, Quantitation, and Analysis with Multiplex Immunoassays [Video]

Scientists studying biomarkers associated with human diseases and drug responses commonly use targeted immunoassays for marker detection and quantitation. Challenges associated with conventional detection methods such as Western blotting and ELISAsinclude limitations imposed by small sample volume due to use of rodent models andthe need for greater sensitivity than conventional test formats. The introduction of multiplex xMAP technology (Luminex) that combines advanced fluidics, optics, and digital signal processing with microsphere technology has enabledmultiplexed assay capabilities and enables acquisition of more data in less time than other bioassay formats, with comparable results to ELISA. Featuring a flexible, open-architecture design, xMAP can be configured to perform a wide variety of bioassays quickly,cost-effectively, and accurately. Recently, for example, scientists have applied xMAP technology to detection andexpression of cytokine expression and secretion in lymphocyte samples from mouse andhuman sources, detecting over 20 different cytokines in samples smaller than 50 uL. Thistechnology has also allowed assessment of cytokine expression in human diseases,before and after immunization and in the healthy general population, as well as thestudy of various mouse models of autoimmune diseases. This multiplexed cytokine assay allows generation of large amounts of data andtherefore new analyses, which result in new insights into the roles of cytokines in healthand disease. In this webinar, investigators will describe how Thermo Fisher Scientifics CytokineHuman 30-Plex Panel for the Luminex platform, was used to demonstrate pharmacologicalinhibition of G protein-coupled estrogen receptor (GPER) as measured by a decrease inpro-inflammatory cytokines. Scientists will also describe how ongoing multiplexassay development for cancer-specific cytokine and autoantibody immunoassaysmay enable differentiation of lung cancer subtypes in patients. In this webinar you will learn: How, by measuring 30 analytes simultaneously, the Luminex assay panel helps provide more data from each sample, saving both money and time compared to more traditional systems (such as ELISA) used in research. How multiplex cytokine kits can detect changes in proinflammatory cytokines in very small volumes of blood samples (less than 50 uL). How one lab has used multiplex cytokine kits to detect rapid and transient activation of intracellular responses of the GPER to agonist binding. How one multiplex assay developer continues to expand applications of this technology to include disease-specific biomarkers for prognostic applications in lung cancer. Who Should Attend: Immunoassay developers Drug development scientists Cellular biochemists Cellular immunologists Core laboratory scientists Scientists studying mechanisms of inflammatory and metabolic diseases